Literature DB >> 11796352

Protective efficacy of a sulfated sialyl lipid (NMSO3) against human rotavirus-induced diarrhea in a mouse model.

Kazuo Takahashi1, Kazutaka Ohashi, Yurika Abe, Shuichi Mori, Koki Taniguchi, Takusaburo Ebina, Osamu Nakagomi, Masaki Terada, Shiro Shigeta.   

Abstract

Antiviral activity of sulfated sialyl lipid (NMSO3) against human rotavirus (RV) was examined in vitro and in vivo. NMSO3 inhibited the replication of four major serotypes (G1 to G4) of human rotavirus with a low 50% effective concentration of 1 to 5 microg/ml and 50% cytotoxic concentration of 153 microg/ml when determined by plaque assays with MA104 cells. Exposure of NMSO3 to HCl (pH 2.0) for 30 min exhibited no loss of anti-RV activity. Time-of-addition experiments revealed that NMSO3 inhibited the adsorption of four serotypes of RV to MA104 cells. Furthermore, an assay of virus binding with radiolabeled RVs revealed that NMSO3 inhibited the binding of virus to MA104 cells, suggesting that NMSO3 may bind to VP4 and/or VP7. Prophylactic oral administration of NMSO3 (10 microg three times per day, 4 days) to five suckling mice starting 30 min before inoculation of MO strain (3 x 10(6) PFU/mouse) prevented the development of diarrhea. Four of five mice showed no stool or brown formed stool, and only one mouse showed brown soft stool, while water treatment caused watery diarrhea in all five mice. The mean titer of antibody to RV in mice which received NMSO3 at 10 microg three times per day for 4 days was significantly lower than that of untreated, infected mice. NMSO3 is a promising candidate for the prophylactic treatment of human RVs.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11796352      PMCID: PMC127020          DOI: 10.1128/AAC.46.2.420-424.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

1.  Protease inhibitors prevent the development of human rotavirus-induced diarrhea in suckling mice.

Authors:  T Ebina; K Tsukada
Journal:  Microbiol Immunol       Date:  1991       Impact factor: 1.955

2.  Hyperimmune cow colostrum reduces diarrhoea due to rotavirus: a double-blind, controlled clinical trial.

Authors:  A K Mitra; D Mahalanabis; H Ashraf; L Unicomb; R Eeckels; S Tzipori
Journal:  Acta Paediatr       Date:  1995-09       Impact factor: 2.299

3.  Diarrhoea in mice infected with a human rotavirus.

Authors:  V S Gouvea; A A Alencar; O M Barth; L de Castro; A M Fialho; H P Araújo; S Majerowicz; H G Pereira
Journal:  J Gen Virol       Date:  1986-03       Impact factor: 3.891

Review 4.  Rotavirus vaccines: success by reassortment?

Authors:  R I Glass; J Gentsch; J C Smith
Journal:  Science       Date:  1994-09-02       Impact factor: 47.728

5.  Gastroenteritis in suckling mice caused by human rotavirus can be prevented with egg yolk immunoglobulin (IgY) and treated with a protein-bound polysaccharide preparation (PSK).

Authors:  T Ebina; K Tsukada; K Umezu; M Nose; K Tsuda; H Hatta; M Kim; T Yamamoto
Journal:  Microbiol Immunol       Date:  1990       Impact factor: 1.955

6.  Rotavirus gastroenteritis. Clinical and laboratory features and use of the Rotazyme test.

Authors:  A Kovacs; L Chan; C Hotrakitya; G Overturf; B Portnoy
Journal:  Am J Dis Child       Date:  1987-02

7.  Clinical and epidemiological features of acute gastroenteritis caused by human rotavirus subgroups.

Authors:  A Chakravarti; S Kumar; S K Mittal; S Broor
Journal:  J Diarrhoeal Dis Res       Date:  1992-03

8.  Determinants of rotavirus stability and density during CsCl purification.

Authors:  D Y Chen; R F Ramig
Journal:  Virology       Date:  1992-01       Impact factor: 3.616

9.  Clinical features of acute infantile gastroenteritis associated with human rotavirus subgroups I and II.

Authors:  A D Steele; P Bos; J J Alexander
Journal:  J Clin Microbiol       Date:  1988-12       Impact factor: 5.948

10.  Oral administration of human serum immunoglobulin in immunodeficient patients with viral gastroenteritis. A pharmacokinetic and functional analysis.

Authors:  G A Losonsky; J P Johnson; J A Winkelstein; R H Yolken
Journal:  J Clin Invest       Date:  1985-12       Impact factor: 14.808

View more
  7 in total

1.  Development of liposomal nanoconstructs targeting P-selectin (CD62P)-expressing cells by using a sulfated derivative of sialic acid.

Authors:  Saotomo Itoh; Kumi Kawano; Kana Takeshita; Yoshie Maitani; Tsutomu Tsuji
Journal:  Pharm Res       Date:  2014-05-03       Impact factor: 4.200

Review 2.  Targeting RSV with vaccines and small molecule drugs.

Authors:  Heather M Costello; William C Ray; Supranee Chaiwatpongsakorn; Mark E Peeples
Journal:  Infect Disord Drug Targets       Date:  2012-04

3.  Coexpression of hepatitis C virus E1 and E2 chimeric envelope glycoproteins displays separable ligand sensitivity and increases pseudotype infectious titer.

Authors:  Keith Meyer; Aster Beyene; Terry L Bowlin; Arnab Basu; Ranjit Ray
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

4.  Evaluation of antirotavirus activity of flavonoids.

Authors:  Luciane Anita Savi; Thiago Caon; Ana Paula de Oliveira; Andrea Michel Sobottka; Wolfgang Werner; Flávio Henrique Reginatto; Eloir Paulo Schenkel; Célia Regina Monte Barardi; Cláudia Maria Oliveira Simões
Journal:  Fitoterapia       Date:  2010-07-24       Impact factor: 2.882

Review 5.  Role of sialic acids in rotavirus infection.

Authors:  Pavel Isa; Carlos F Arias; Susana López
Journal:  Glycoconj J       Date:  2006-02       Impact factor: 2.916

6.  Broad-spectrum neutralization of avian influenza viruses by sialylated human milk oligosaccharides: in vivo assessment of 3'-sialyllactose against H9N2 in chickens.

Authors:  Ramesh Prasad Pandey; Dae Hee Kim; Jinsuk Woo; Jaeyoung Song; Sang Ho Jang; Joon Bae Kim; Kwang Myun Cheong; Jin Sik Oh; Jae Kyung Sohng
Journal:  Sci Rep       Date:  2018-02-07       Impact factor: 4.379

7.  Multiple-dose therapy with bovine colostrum confers significant protection against diarrhea in a mouse model of human rotavirus-induced gastrointestinal disease.

Authors:  M Inagaki; M Yamamoto; T Yabe; K Uchida; M Kawasaki; T Nakagomi; O Nakagomi; N Minamoto; Y Kanamaru
Journal:  J Dairy Sci       Date:  2012-11-29       Impact factor: 4.034

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.